Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 91-2700, Iss. 11, 2015-11 ,pp. : 1268-1279

John Wiley & Sons Inc

Access to resources Recommend Favorite

An open‐label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 12, 2015-12 ,pp. : 1395-1405

John Wiley & Sons Inc

Access to resources Recommend Favorite

Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia

By Tzeng Tsang-Bin   Schneck Dennis W.   Birmingham Bruce K.   Mitchell Patrick D.   Zhang Harry   Martin Paul D.   Kung Li-Pin  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2575-2585

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of Model‐Based Prediction of Pharmacokinetics in the Renal Impairment Population

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 58, Iss. 3, 2018-03 ,pp. : 364-376

John Wiley & Sons Inc

Access to resources Recommend Favorite

Garenoxacin pharmacokinetics in subjects with renal impairment

By Krishna Gopal   Gajjar Diptee   Swan Suzanne   Marbury Thomas   Grasela Dennis M.   Wang Zaiqi  

Current Medical Research and Opinion, Vol. 23, Iss. 3, 2007-03 ,pp. : 649-657

Informa Healthcare

Access to resources Recommend Favorite